All In Biotech

Drug Trial Radar · NCT05841160

Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

A Randomized, Double-Blind, Placebo- and Positive Controlled, Crossover, Thorough QT/QTc Study to Evaluate the Effects of a Therapeutic and Supratherapeutic Dose of Ecopipam (EBS-101) on Cardiac Repolarization in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Mar 15, 2023

Primary completion

May 7, 2023

Study completion May 12, 2023

Sponsor

Lead sponsor
Emalex Biosciences Inc.Industry
Sponsor type
Industry
Collaborators
PPD Development, LP; Clario
First posted
May 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

THOROUGH QT/QTc STUDY TO EVALUATE THE EFFECTS OF ECOPIPAM (EBS-101) ON CARDIAC REPOLARIZATION

Conditions

  • QT/QTc

Interventions

  • Ecopipam HydrochlorideDrug

    oral tablets

  • MoxifloxacinDrug

    oral tablet

  • PlaceboDrug

    oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate ecopipam's effect on the QTc interval after administration of therapeutic and supratherapeutic doses, compared to placebo as a negative control using C-QTc analysis.Time frame: Up to Day 25

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD Austin Phase 1 Clinical Research Unit

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.